BRISBANE, Calif. / Dec 18, 2024 / Business Wire / CareDx, Inc. (Nasdaq: CDNA) - The Transplant Company™ — a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers — today announced that the company will participate in the upcoming 43rd Annual J.P. Morgan Healthcare Conference in San Francisco.
CareDx’s management is scheduled to present on Tuesday, January 14, 2025, at 4:30 p.m. Pacific Time (7:30 p.m Eastern Time). To listen to the webcast, please visit the Events & Presentations section of CareDx’s Investor Relations website at: investors.caredx.com.
About CareDx – The Transplant Company
CareDx, Inc., headquartered in Brisbane, California, is a leading precision medicine solutions company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers. CareDx offers testing services, products, and digital healthcare solutions along the pre- and post-transplant patient journey and is the leading provider of genomics-based information for transplant patients. For more information, please visit: www.CareDx.com.
| Last Trade: | US$17.62 |
| Daily Change: | -0.60 -3.29 |
| Daily Volume: | 512,969 |
| Market Cap: | US$944.960M |
February 26, 2025 February 20, 2025 February 13, 2025 | |
Amneal Pharmaceuticals is a fully-integrated essential medicines company. We make healthy possible through the development, manufacturing, and distribution of generic and specialty pharmaceuticals. The Company has a diverse portfolio of over 250 products in its Generics segment and is expanding across...
CLICK TO LEARN MORE
Recursion Pharmaceuticals is a clinical stage TechBio company leading the space by decoding biology to industrialize drug discovery. Enabling its mission is the Recursion OS, a platform built across diverse technologies that continuously expands one of the world’s largest....
CLICK TO LEARN MORE
